Amicus logo

Amicus

Stock
Stock
Ticker: FOLD
FOLD

Price

Price

CHART BY

Frequently asked questions

Amicus's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -0.0886. EPS indicates the company's profitability on a per-share basis.
Currently, 1 analysts cover Amicus's stock, with a consensus target price of $14.50. Analyst ratings provide insights into the stock's expected performance.
Over the trailing twelve months, Amicus reported a revenue of $634.21M.
Amicus's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $41.95M. EBITDA measures the company's overall financial performance.
Amicus has a free cash flow of $29.85M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
Amicus employs approximately 511 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.

Financials

EPS (TTM) 
-0.0886
Revenue (TTM) 
$634.21M
EBITDA (TTM) 
$41.95M
Free Cashflow (TTM) 
$29.85M

Analyst Ratings

The price target is $14.50 and the stock is covered by 1 analysts.

Buy

0

Hold

1

Sell

0

Information

Amicus Therapeutics, Inc. is a biotechnology company, which engages in discovering, developing, and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.

Employees
511
Industries
Major Pharmaceuticals
Sector
Health Care

Identifier

Primary Ticker
FOLD

Knockouts

Real-time data from LSX · Fundamentals & EOD data from FactSet
Join the conversation